Telik, Inc. (Nasdaq: TELK) announced that its novel small molecule proteasome inhibitor program met a preclinical development milestone by demonstrating ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE